CELL & GENE MEETING ON THE MESA 2022 NEWS
Gene editing advances continue a pace, but progress is still early: panel
October 17, 2022 -- With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are looking forward to other near- and longer-term breakthrough technologies on the horizon.
October 17, 2022 -- With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are looking forward to other near- and longer-term breakthrough technologies on the horizon.
Cell & Gene Meeting on the Mesa attendance record | Opportunities, challenges highlighted
October 14, 2022 -- Science Advisory Board was onsite this week at the 2022 Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, and organized by the Alliance for Regenerative Medicine (ARM).
October 14, 2022 -- Science Advisory Board was onsite this week at the 2022 Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, and organized by the Alliance for Regenerative Medicine (ARM).
Roadblocks continue to hamper CGT companies as they look to commercialize their products
October 14, 2022 -- The cell and gene therapy (CGT) sector will continue to face investment and regulator challenges in the near term. That’s the consensus of companies in the space who participated in a workshop at this week’s Cell & Gene Meeting on the Mesa in Carlsbad, CA.
October 14, 2022 -- The cell and gene therapy (CGT) sector will continue to face investment and regulator challenges in the near term. That’s the consensus of companies in the space who participated in a workshop at this week’s Cell & Gene Meeting on the Mesa in Carlsbad, CA.
FDA biologics chief outlines ways to remove barriers to cell and gene therapies
October 13, 2022 -- At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level.
October 13, 2022 -- At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level.
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
October 12, 2022 -- Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders.
October 12, 2022 -- Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders.
Panel to focus on pluripotent stem cells at Cell & Gene Meeting on the Mesa
October 11, 2022 -- A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies.
October 11, 2022 -- A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies.
6 startups to compete for $250K grand prize at 2022 BioTools Innovator capstone event
October 10, 2022 -- BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa.
October 10, 2022 -- BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa.
Meeting on the Mesa comes at pivotal time for cell and gene therapy industry
October 5, 2022 -- Stakeholders from around the cell and gene therapy sector will come together during the Alliance for Regenerative Medicine’s hybrid 2022 Meeting on the Mesa, October 11-13 in Carlsbad, CA, to discuss the opportunities and challenges facing the industry.
October 5, 2022 -- Stakeholders from around the cell and gene therapy sector will come together during the Alliance for Regenerative Medicine’s hybrid 2022 Meeting on the Mesa, October 11-13 in Carlsbad, CA, to discuss the opportunities and challenges facing the industry.
FDA creates “Super Office” to manage growing cell and gene therapy workload
October 4, 2022 -- The U.S. Food and Drug Administration (FDA) has elevated and reorganized its Office of Tissues and Advanced Therapies to a “Super Office” within the Center of Biologics Research and Evaluation to meet its growing cell and gene therapy workload.
October 4, 2022 -- The U.S. Food and Drug Administration (FDA) has elevated and reorganized its Office of Tissues and Advanced Therapies to a “Super Office” within the Center of Biologics Research and Evaluation to meet its growing cell and gene therapy workload.
Mixed bag so far in 2022 for cell and gene therapy sector: ARM report
October 3, 2022 -- So far, 2022 has been a mixed bag for the cell and gene therapy sector on the regulatory and investment fronts, according to a new report from the Alliance for Regenerative Medicine (ARM).
October 3, 2022 -- So far, 2022 has been a mixed bag for the cell and gene therapy sector on the regulatory and investment fronts, according to a new report from the Alliance for Regenerative Medicine (ARM).